Wockhardt shares surged 7% on Tuesday, September 8, marking the fifth consecutive day of gains according to latest reports from Business Standard. The pharmaceutical company's stock is currently quoting at ₹2,214, up 0.27% on the day as of 12:44 IST on the NSE. The stock has demonstrated remarkable momentum, rising 7.1% to hit an intraday high of ₹2,236 and trading 5% higher at ₹2,192 at 1:20 pm. The stock has gained for seven of the previous 10 trading sessions and emerged as the biggest gainer on the Nifty Pharma index in intraday trade on Monday.
The stock has delivered impressive returns across multiple timeframes, rising nearly 19% since the beginning of this month as reported by CNBC TV18. Over the longer term, Wockhardt shares have gained over 56% since the beginning of the year and over 52% over the trailing 12-month period. The stock has added 14.64% in the last one month and remains 9% away from its 52-week high of ₹2,422.30, indicating potential for further upside movement. The PE ratio stands at 108.36 based on TTM earnings ending June 26.
The pharmaceutical company reported robust financial results for the June quarter, with consolidated net profit of ₹106 crore compared to a ₹90 crore loss in the year-ago quarter, according to CNBC TV18. Revenue from operations rose 26% to ₹929 crore from ₹738 crore year-on-year. The company's EBITDA increased significantly to ₹192 crore from ₹72 crore a year earlier, while EBITDA margin improved substantially to 20.67% from 9.76%.
On June 1, Wockhardt's shares had surged more than 19% intraday after the US Food and Drug Administration (USFDA) approved its antibiotic WCK 5222, marketed as Zaynich, for treating complicated urinary tract infections, as reported by CNBC TV18. The approval made Zaynich the first antibiotic discovered and developed in India to receive US regulatory clearance. The drug had received Fast Track and Qualified Infectious Disease Product designations, while Wockhardt filed its New Drug Application in October 2025 and secured approval in less than a year.
Wockhardt's performance stands out against broader market weakness, with the benchmark NIFTY down around 0.5% and Sensex at 75,654.76, down 0.63% on the day. The Nifty Pharma index has added 1.46% in the last one month and is currently quoting at 26,675.5, up 0.72% on the day. The stock's volume stood at 9.14 lakh shares today, compared to the daily average of 10.16 lakh shares in the last one month, indicating moderate trading activity during the current session.
